Daniel Lochner Buys Shares of TECX $TECX
Key Points
- Daniel Lochner bought 7,500 shares of Tectonic Therapeutic, Inc. ($TECX).
- $TECX last traded around $30.28.
Daniel Lochner, Chief Financial Officer at Tectonic Therapeutic, Inc. ($TECX), bought 7,500 shares at an average price of $0.00. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Tectonic Therapeutic, Inc. ($TECX) Stock
Tectonic Therapeutic, Inc. Earnings
Analysts Set New Price Targets
About Tectonic Therapeutic, Inc.
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.